0372 Arousability of Insomnia Patients is Not Impacted by the Orexin Antagonist Suvorexant (10 mg and 20 mg)
نویسندگان
چکیده
منابع مشابه
Suvorexant, a dual orexin receptor antagonist for the management of insomnia.
Suvorexant, a dual orexin receptor antagonist for the management of insomnia.
متن کاملEzetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
BACKGROUND Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD). METHODS This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary hypercholesterolemia and established CHD who were taking a stable daily dose of simvastatin 20 mg. Patients were randomized ...
متن کاملRabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis.
BACKGROUND Several randomized controlled trials (RCTs) have compared endoscopic and symptomatic relapses in patients with erosive gastroesophageal reflux disease (GERD). We have summarized current evidence for rabeprazole 10 or 20 mg once daily for GERD maintenance treatment over 1 or 5 years. METHODS MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched, throu...
متن کاملReview of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Pseudobulbar Affect
Pseudobulbar affect (PBA) is a dysfunction of emotional expression characterized by involuntary outbursts of crying or laughing disproportionate or unrelated to mood, occurring in patients with various underlying neurologic disorders. This review describes the clinical data supporting dextromethorphan (DM) hydrobromide combined with quinidine sulfate (Q) as treatment of PBA and briefly surveys ...
متن کاملSuvorexant: a promising, novel treatment for insomnia
Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sleep
سال: 2019
ISSN: 0161-8105,1550-9109
DOI: 10.1093/sleep/zsz067.371